MétaCan
Menu
Back to cohort
Record W2912461211 · doi:10.1093/ecco-jcc/jjy222.025

OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study

2019· article· en· W2912461211 on OpenAlex
Séverine Vermeire, J F Colombel, Brian G. Feagan, William J. Sandborn, Bruce E. Sands, Silvio Danese, Geert D’Haens, Remo Panaccione, David T. Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A. Lirio, Edward V. Loftus

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsUniversity of CalgaryWestern University
Fundersnot available
KeywordsVedolizumabMedicineUlcerative colitisInternal medicineAdverse effectExacerbationClinical endpointInflammatory bowel diseaseGastroenterologySurgeryDiseaseClinical trial

Abstract

fetched live from OpenAlex

Vedolizumab (VDZ), a gut-selective, humanised, α4β7 integrin monoclonal antibody, was approved in 2014 in the USA and EU to treat moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). GEMINI long-term safety (LTS) is the longest VDZ continuous treatment study to date and provides unique data for VDZ therapeutic profiling. We report the final GEMINI LTS safety and efficacy findings. GEMINI LTS was a multi-national, multi-centre, open-label, Phase 3 study (NCT00790933/EudraCT 2015-000480-14). Patients with UC or CD received VDZ 300 mg IV every 4 weeks after they completed or withdrew from a Phase 2 study or one of the GEMINI Phase 3 studies or enrolled as VDZ-naïve de novo patients. Treatment continued until study completion or loss to follow-up (eg, after VDZ approval or expanded-access programme availability at the local site). Long-term safety was the primary endpoint and efficacy was an exploratory endpoint. A total of 894 patients with UC and 1349 with CD enrolled in GEMINI LTS for a planned treatment duration of 9 years. All patients had received ≥1 prior conventional therapy (Table 1). Adverse events (AEs) occurred in 93% of UC patients and 96% of CD patients; most frequent were UC (36%) and CD (35%) exacerbations and nasopharyngitis (UC, 28%; CD, 25%; Table 2). No new trends were observed for infections, malignancies, infusion-related reactions, or hepatic events. Serious AEs (SAEs) were reported in 31% of UC patients and 41% of CD patients; disease exacerbation was the most frequent SAE in both cohorts (UC, 13%; CD, 17%). VDZ was discontinued due to AEs in 15% of UC patients and 17% of CD patients, with UC or CD exacerbation (9% and 8%, respectively) the most frequent reason for discontinuation. There were no cases of progressive multi-focal leukoencephalopathy and 10 (UC, 4; CD, 6) deaths during the study. Clinical response was maintained long-term in patients who continued to receive VDZ throughout the entire study; however, the efficacy analysis was limited due to the expected, protocol-defined, patient loss to follow-up. The final GEMINI LTS results provide evidence that VDZ has a safety profile suitable for long-term treatment of UC and CD. In this carefully monitored population receiving VDZ in a clinical trial setting, there continue to be no unexpected or new safety concerns. Abstract OP026 – Table 1. Baseline demographics and clinical characteristics. Abstract OP026 – Table 2. Safety overview.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.332
Threshold uncertainty score0.437

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.297
Teacher spread0.273 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it